Member-at-Large Candidate

Dan Bow, Ph.D.
AbbVie, Inc.

Dan Bow, Ph.D. is a senior director and research fellow in the Quantitative, Translational and ADME Sciences (QTAS) organization at AbbVie in North Chicago, Illinois. He leads a global organization of approximately 40 scientists responsible for project support, in vitro ADME, preclinical pharmacokinetics, and translational pharmacokinetics.

Bow provides strategic leadership in drug metabolism and pharmacokinetics (DMPK), including oversight of physiologically based pharmacokinetic (PBPK) modeling and human dose predictions to inform clinical development strategies. His team plays a critical role in enabling program progression from Discovery to the clinic including authorship and review of regulatory submissions. His work has contributed broadly to advancing compounds across the pipeline and strengthening translational decision-making.

With more than 19 years of experience in DMPK sciences, Bow has held roles of increasing responsibility at AbbVie, including leadership of late-stage ADME and PBPK strategy, as well as earlier leadership of drug transporter sciences. He has served as a DMPK project representative on many discovery and development programs and is recognized for his expertise in drug transporters, translational ADME, and the integration of modeling approaches to address complex development challenges.

Bow has a long-standing and sustained commitment to the American Association of Pharmaceutical Scientists (AAPS) and the broader scientific community. He currently serves as chair of the AAPS Scientific Advisory Committee and has previously held multiple leadership roles, including Chair of the Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM) Section and PharmSci 360 Preclinical Development Track Chair. He has also contributed to many committees, workshops, and programming efforts.

In addition to his AAPS involvement, Bow is an active contributor to cross-industry collaborations, including the IQ Consortium, where he has held leadership roles and contributed to initiatives advancing transporter science and translational methodologies. He has authored many peer-reviewed publications and delivered invited presentations at major scientific conferences, contributing to the global advancement of pharmaceutical sciences.

Bow received his Ph.D. in Medical Sciences from the University of Aberdeen, where his research focused on mechanisms of drug-induced nephrotoxicity and renal transporter function. He later conducted research at the National Institute of Environmental Health Sciences and completed postdoctoral training at the University of North Carolina at Chapel Hill, focusing on hepatic transporter biology and in vitro translational models.

Why are you interested in serving AAPS in the capacity of member-at-large and how has your experience prepared you to lead AAPS?

“When I first started out, I never imagined I would eventually lead a global team of drug development scientists in the biopharmaceutical industry. My journey began as a curious graduate student in Scotland, continued through post-doctoral roles in the U.S. government and academia, and ultimately led me to industry in 2007. Early in my career, my first engagement with AAPS provided me the platform to learn, share my work, and feel part of a dynamic scientific community, a connection that has continually shaped my growth as both a scientist and a leader

“Over the years, I have seen firsthand how the membership of AAPS benefits from the rich programming, collaborations, and influence in our scientific field. Having served in volunteer, leadership, and advisory roles, ranging from community involvement to leadership of the Scientific Advisory Committee, I have developed a deep appreciation for the ability of AAPS to connect, support, and inspire its members. Through these experiences, I’ve built a valued network and seen how AAPS drives scientific progress and professional development.

“What excites me most about serving as member-at-large now is the unprecedented pace of change in our field. Advances in artificial intelligence, data science, and the emergence of new modalities are transforming not only how we do science, but also who we are as an organization and how we must evolve to support our members. The challenge, and opportunity, is to ensure AAPS remains a forward-thinking, agile, and dynamic organization. We must proactively seek change where needed, adapt to emerging scientific and professional landscapes, and continually reevaluate how we create value for our diverse membership. Remaining relevant and competitive means not sitting still. It requires that we recognize how rapidly the expectations and needs of pharmaceutical scientists are changing, ensure we offer cutting-edge scientific forums, career development, resources, and foster an inclusive, collaborative environment. We must also strengthen our distinct identity among the many organizations vying for the attention of our scientists, demonstrating why AAPS is the association of choice for those invested in advancing pharmaceutical science.

“As member-at-large, I would champion this vision, drawing on my career experiences, and my deep commitment to our association. I am motivated to work to ensure all members have the opportunity to thrive and to help steer AAPS through this era of rapid transformation so that, together, we continue to improve global health.”